Nigeria’s Emzor Pharmaceutical Industries has raised $19.8 million through a five-year bond to expand its manufacturing capacity.
The fixed-rate Series 1 bond, which carries a 19 percent coupon, was listed on the FMDQ Exchange through Emzor Pharma Funding SPV Plc. The issue was oversubscribed and forms part of a wider N40 billion $29.6 million) bond programme.
The funds will support working capital, expand manufacturing capacity and accelerate the completion of the company’s Active Pharmaceutical Ingredient (API) plant in Sagamu, Ogun State, which will initially produce ingredients for antimalarial medicines.
According to Dr. Stella Chinyelu Okoli, Founder of Emzor , the fundraising marks another milestone in a pharmaceutical business that began as a small chemist shop in Lagos nearly five decades ago.
From a small chemist shop to a major manufacturer
Okoli started Emzor as a small retail chemist shop in Yaba, Lagos, in 1977. She later expanded the business into pharmaceutical manufacturing, with the company incorporated in 1984.
Today, Emzor is one of Nigeria’s major indigenous pharmaceutical manufacturers, with a portfolio of more than 120 products, including analgesics, antimalarials, antibiotics and vitamins.
Her journey from a small retail operation to an industrial pharmaceutical company highlights the growing role of African women in building businesses beyond traditional small and medium-sized enterprises.
Okoli’s business has moved into manufacturing, capital markets and pharmaceutical research and development, areas that require significant long-term investment.
The latest bond is part of that continued expansion.
Emzor bets on local pharmaceutical production
A major focus of the investment is Emzor’s API plant in Sagamu.
APIs are the active substances that make medicines work. African pharmaceutical manufacturers remain heavily dependent on imported APIs and other raw materials, exposing the industry to foreign-exchange shortages, currency fluctuations and international supply-chain disruptions.
Emzor’s Sagamu facility is intended to reduce some of that dependence by manufacturing pharmaceutical ingredients locally.
The company has described the project as the first full-scale antimalarial API manufacturing facility in Africa. The plant is expected to begin with antimalarial ingredients before expanding into APIs for HIV antiretrovirals and other essential medicines.
If completed and successfully scaled, the facility could strengthen Nigeria’s pharmaceutical supply chain and create opportunities for the country to serve other African markets.
Plant faces delays
The Sagamu project has, however, taken longer than initially expected.
Emzor unveiled plans for the approximately $23 million facility in 2024, with reports in March 2025 indicating that operations were expected to begin later that year.
By August 2025, the expected opening had shifted to early 2026.
The latest financing is now expected to accelerate completion, although the company has not announced a new commissioning date.
The delay adds significance to the latest fundraising, particularly given the bond’s 19 percent coupon over five years.
A broader story about women in business
Okoli’s rise is significant in a continent where women entrepreneurs play a major role in economic activity but often face difficulties accessing the capital required to scale businesses into larger industrial enterprises.
Emzor’s evolution shows what can happen when a woman-owned business moves beyond retail into manufacturing and strategic sectors of the economy.
Her story also reflects the importance of long-term entrepreneurship.
What began as a small chemist shop has grown into a pharmaceutical company now investing in the production of the raw materials used to manufacture essential medicines.
For African women entrepreneurs, that progression offers an important lesson: starting small does not have to mean staying small.
Why the investment matters
The Emzor bond comes as African countries seek to strengthen local manufacturing and reduce reliance on imported essential medicines and pharmaceutical inputs.
For Nigeria, increasing domestic production of APIs could help build a more resilient pharmaceutical industry and reduce exposure to global supply disruptions.
For Emzor, the Sagamu facility represents a significant capital investment and an opportunity to move further up the pharmaceutical value chain.
And for Okoli, the project adds another chapter to a nearly 50-year entrepreneurial journey.
From a chemist shop in Lagos to a multibillion-naira capital raise, her story illustrates how African women can build businesses that extend beyond individual commercial success to influence manufacturing, healthcare, employment and economic resilience.
Stella Okoli’s journey is ultimately a story about scale: the scale of a woman’s ambition, the scale of an African business and the possibility of building industries that address Africa’s own needs.
About the Author
